Dermatitis News

MILAN — Remibrutinib reduced the need for second-generation H1 antihistamines as a rescue medication in patients with chronic spontaneous urticaria across all doses in a 12-week study.

MILAN — A basket study of a new topical phosphodiesterase 4 inhibitor demonstrated efficacy superior to that of placebo in mild to moderate plaque psoriasis.

MILAN — Patients with atopic dermatitis of the head and neck who did not have success with topical therapy experienced greater improvement with rocatinlimab treatment.

MILAN — Maintenance dosing of lebrikizumab every 4 weeks showed similar efficacy as dosing every 2 weeks in patients with atopic dermatitis, according to a presentation at the European Academy of Dermatology and Venereology Congress.

MILAN — Atopic dermatitis patients with lower disease severity and better quality of life also were associated with lower clinical burdens and work impairment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

MILAN — Adult-onset dermatitis has distinct TH1 activation compared with adults who have childhood-onset atopic dermatitis, showing two separate endotypes defined by age of onset.

Although treatment was well tolerated, astegolimab did not effectively improve primary or secondary outcome measurements in atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology.

MILAN — Long term use of remibrutinib was safe and well tolerated for patients with chronic spontaneous urticaria, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

Patients with chronic spontaneous urticaria experience more pleasure from scratching itches compared with patients with other skin conditions, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Dupilumab had good overall survival for up to 3 years in patients with atopic dermatitis, according to a study.